Despite promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable opposition from managed care entities. Such companies are often building barriers to reimbursement, like significant expense requirements and prior authorization that limit patient availabilit